Peginterferon Alfa-2A Injection shortage (resolved)
Peginterferon Alfa-2A Injection is not in an active FDA shortage right now. The most recent status on record was “Resolved”. This page is kept for history. This page was last refreshed from FDA data on Sep 21, 2026.
Peginterferon Alfa-2A Injection is not in an active FDA shortage right now (last status: “Resolved”) — confirm current availability with your pharmacy.
Do you take this drug? See the ‘What to do’ recommendation from Dr. Brian Staiger, PharmD →What’s in shortage — at a glance
These figures count only the manufacturers that reported this shortage to the FDA — not every company that makes Peginterferon Alfa-2A Injection. Other makers that haven’t reported a problem are shown in the green card below.
Shortage timeline
-
Aug 27, 2026Shortage resolvedFDA no longer lists this as an active shortage.
-
Jan 24, 2025First reported to the FDA2 products first listed.
Built from FDA posting and update dates. The end date FDA publishes is the posting/update date, not a true resolution date, so durations are approximate.
What exactly is on backorder — by manufacturer
Manufacturer: pharmaand GmbH (pharma&) 📞 800-506-8501, email: [email protected] 2 NDCS click to expand
| Status | NDC / product | Strength / size | Availability | Related information | Reason |
|---|---|---|---|---|---|
| Resolved | Pegasys, Injection, 180 ug/.5 mL (NDC 82154-0451-4) | — | — | — | — |
| Resolved | Pegasys, Injection, 180 ug/1 mL (NDC 82154-0449-1) | — | — | — | — |
These rows are manufacturer reports to the FDA for Peginterferon Alfa-2A Injection — they do not necessarily cover every manufacturer that makes this drug. A company appears here only if it told the FDA it has a supply problem, so other makers may still have stock. That’s the basis for the Where else can I get Peginterferon Alfa-2A Injection? options further down this page.
Why is Peginterferon Alfa-2A Injection in shortage?
The shortage of this specific product comes down to a regulatory delay — meaning there's some kind of hold-up in the approval or compliance process that has to be resolved before more product can be supplied. pharma& (pharmaand GmbH) reported this is affecting only one particular version of their Pegasys injection: the 180 mcg/1 mL package size. According to what they've shared with the FDA, they expect to have a clearer timeline for restocking sometime in Q1 2027 or earlier.
It's worth knowing that the other version — 180 mcg/0.5 mL — is still listed as available from this same manufacturer. So it's really just that one specific package size that's caught up in this regulatory hold-up right now, not the medication as a whole from this company.
Based on the manufacturer-reported reason(s) and notes on file with the FDA for Peginterferon Alfa-2A Injection, summarized in plain English by HelloPharmacist. A drug can be short for more than one reason, and the FDA updates these as manufacturers report changes.
What should I do if I take Peginterferon Alfa-2A Injection?
Peginterferon Alfa-2A injection (brand name Pegasys) is currently on the FDA shortage list. Since this involves an injectable medicine, I want to walk you through the details calmly so you can find the strength you use.
The two strengths are affected differently. The 180 ug/0.5 mL strength still has an available source. The 180 ug/1 mL strength currently has no available source. If you use the 0.5 mL prefilled syringe, supply is reported as available; if you use the 1 mL form, that is the one on hold right now.
The reported reason is a regulatory delay, and this situation has lasted over a year. For the affected 180 ug/1 mL strength, the manufacturer notes a replenishment timeline to be confirmed sometime in Q1 2027 or earlier. This report reflects one manufacturer, so this is not a comment on every possible source.
Here are your next steps:
- Do not stop, skip, or change your dose on your own.
- If you use the 0.5 mL strength, ask your pharmacy to order it — they can check wholesalers and manufacturers.
- If your strength cannot be found, ask your prescriber or pharmacist about options, such as a clinician-chosen adjustment.
- Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle these calls.
This is general, national information and may not match your local pharmacy's stock.
- Don’t stop or change the medication on your own — talk to your prescriber first.
- If this is part of an ongoing or essential regimen (for example HIV treatment or prevention, seizure, heart, transplant, diabetes or mental-health medicines), do not skip or ration doses — contact your pharmacist or prescriber right away to arrange continued supply before you run out.
- Ask your pharmacy to check other manufacturers, strengths, package sizes, and nearby stores.
- Ask your prescriber whether a different strength, formulation, or the brand/generic version is appropriate.
Uses, dosing, side effects, prices, and the complete FDA label — written in plain English and pharmacist-reviewed.
Other drugs in the same treatment class
These are different medicines — not other versions of Peginterferon Alfa-2A Injection — that fall in the same broad treatment class (hepatitis c treatment agents) . They are not automatic substitutes: they can differ in how they work, dosing, effectiveness, side effects and what they’re approved to treat. Do not switch on your own. This list is for information only — ask your prescriber or pharmacist whether any of them is appropriate for you.
Identity & classification
Where does this data come from?
Other antiviral shortages
Peginterferon Alfa-2A Injection shortage FAQs
Is Peginterferon Alfa-2A Injection in shortage?
Which products are affected?
When will Peginterferon Alfa-2A Injection be available again?
What should I do if I take Peginterferon Alfa-2A Injection?
Still have a question about the Peginterferon Alfa-2A Injection shortage?
Ask a pharmacist about this shortage →View Peginterferon Alfa-2A Injection on the FDA drug-shortage database →
Where does this data come from?
/drug/shortages) — drug, manufacturer & contact, NDC/product, status, availability, reason, therapeutic category and posting/update dates. Current / To Be Discontinued = active; Resolved is kept for history. The Supply-Risk rating is assessed per active ingredient and adds the FDA NDC Directory (still-marketed manufacturers by ingredient & form); same-medicine and equivalent products use First Databank classification + CMS NADAC pricing; Medicaid use + most-affected states come from CMS Medicaid State Drug Utilization Data. Reference only — confirm current status with the manufacturer or FDA before acting on it.